MedImmune reports earnings

MEDI reported a third quarter loss per share of $0.22, excluding charges associated with ending its deal with Wyeth (WYE) for FluMist. The Street had expected a loss of $0.21. Revenues were $93 million in the third quarter, down 7% from $99 in the same period last year, when MEDI received about $17 million in other revenues including milestones and other payments from WYE for FluMist.

Sales were up 12% quarter over quarter to $92 million from $82 million. Sales of Synagis palivizumab to prevent pediatric RSV infection increased 25% to $61 million. Chemoprotectant Ethyol amifostine posted third quarter sales of $21 million, up 4% quarter over quarter. ...